Enoxacin is a potent quinolone derivative with marked activity against gram-negative bacteria and staphylococci. The oral preparation has a potential role in treatment of gram-negative-bacterial lower respiratory infections if found to give adequate bronchial (sputum) concentrations. A study was done to determine the concomitant serum and bronchial concentrations of oral enoxacin after dosing with (i) 600 mg, single dose; (ii) 400 mg, single dose; and (iii) 400 mg every 12 h, four doses. Blood and bronchial secretions were collected from 20 patients predose and 2, 5, and 9 h postdose. Bronchial secretions were obtained from tracheostomies, endotracheal tubes, or bronchoscopy. Levels of enoxacin in serum and sputum were measured by high-pressure liquid chromatography. Mean peak bronchial secretion levels were similar for the 400-mg dose schedules (2.2 and 2.4 ,ug/ml) but were significantly higher with the 600-mg dose (4.0 ,ug/ml) (P < 0.05). Significant concentrations in bronchial secretions were still achievable at 9 h postdose (1.3 to 2.3 ,ig of enoxacin per ml). The mean ratios of enoxacin concentrations in sputum to those in serum at various time intervals for all groups were as follows: at 2 h, 0.55 ± 0.34; at 5 h, 1.04 ± 0.72; at 9 h, 0.97 ± 0.62. Considering that most gram-negative bacteria are inhibited by 1.0 gug of enoxacin per ml in vitro, this study shows that oral enoxacin in practical doses achieves a concentration in bronchial secretions that is adequate to treat most gram-negativebacterial lower respiratory infections.
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Enoxacin, an investigational quinolone derivative, has marked in vitro activity against many respiratory pathogens (P. Wise, Quinolones Bull. June:1-2, 1985) such as Staphylococcus aureus (including methicillin-resistant strains), Haemophilus influenzae (including ,B-lactamase-positive strains), most gram-negative bacilli (such as Klebsiella and Pseudomonas spp., etc.), and Legionella pneumophila. However, it has poor activity against pneumococci and other streptococci.
Enoxacin has been found to give reasonably good levels in blood after oral dosing (14) ; if adequate levels in bronchial secretion (sputum) are found, it would have a potential role in the treatment of gram-negative-bacterial lower respiratory infections. Although the aminoglycosides and newer cephalosporins provide adequate therapy, there is still a need for oral preparations which will allow initiation of treatment in the home or office and for earlier discontinuation of parenteral therapy. This would facilitate earlier discharge from the hospital and be of benefit in reducing the cost of medical care. A study was done to determine the concomitant concentrations in serum and sputum (bronchial secretion) after different oral doses of enoxacin.
( bronchoscopy. Patients were alert and able to communicate verbally or in writing, and informed, written consent was obtained from all patients.
Of these patients, 21 had tracheostomy or endotracheal tubes; in 2 patients, sputum was obtained from bronchoscopy. All patients had either pneumonia or tracheobronchitis.
Patients were randomized to receive oral enoxacin (supplied by Parke-Davis Canada Inc.) as follows: (i) 600 mg, single dose; (ii) 400 mg, single dose; (iii) 400 mg every 12 h, four doses. Two groups of eight patients received 400-and 600-mg oral doses of enoxacin, respectively, and seven patients received 400 mg every 12 h for four doses. Three patients were excluded from analysis because of evidence of aspiration, esophagotracheal fistula, or dilution of sputum at bronchoscopy. Two of these patients received 600-mg single doses, and one patient received the 400-mg multiple-dose regimen. Blood and sputum samples were collected predose and 2, 5, and 9 h postdose (after the last dose). Samples in the bronchoscopy patients were collected only at 2 h postdose. Sputum samples (tracheobronchial secretion) were collected undiluted directly from the trachea or bronchus by aspiration. Samples of serum and sputum were frozen at -70°C until ready for processing and analysis. The volume of sputum was measured apd then mixed with twice the volume of 0.1 M phosphate buffer (pH 6.0). This mixture was then homogenized and liquified with a Polytron Homogenizer [Brinkmann Instruments (Canada) Ltd., Rexdale, Ontario]. Laboratory tests included complete blood count, platelet count, serum creatinine, alkaline phosphatase, serum aspartate aminotransferase, and bilirubin, before and after dosing.
Assay. Serum and sputum assays for enoxacin were done by high-pressure liquid chromatography. Standards were prepared in a fashion similar to test samples, from control sputa and pooled sera, as well as phosphate buffer. (Table 2) .
The concomitant concentrations of enoxacin in sputum and serum for the different dosage schedules are shown in Table 2 . Peak concentrations of enoxacin in serum were achieved at 2 h postdose. The mean peak concentrations in serum after the 400-mg dose schedules varied from 2.3 ,ug/ml (for single dose) to 3.8 p.g/ml (after multiple dose) (P < 0.01). This may represent some accumulation after multiple dos- Mean concn (,ug/ml ± SD) in sputum/mean concn (,ug/ml ± SD) in serum at:
400 mg, 4 doses (6) 2.1 ± 1.2/3.8 ± 0.3 2.4 ± 1.4/2.5 ± 0.7
1.3 ± 0.8/1.6 ± 0.6 400 mg, 1 dose (8) 1.7 ± 1.3/2.3 ± 0.8 2.2 ± 1.9/1.9 ± 0.6 1.5 ± 0.7/1.3 ± 0.6 600 mg, 1 dose (6) 2.5 ± 2.9/4.0 ± 1. ing. The mean peak concentration in serum after the 600-mg single dose was 4.0 pug/ml, not significantly higher than after multiple doses of 400 mg of enoxacin. The mean peak concentration in sputum after 600-mg doses of enoxacin (4.0 ,g/ml) was significantly higher (P < 0.05) than the peak concentrations in sputum after the 400-mg dose schedules (2.2 and 2.4 ,ug/ml). Time curves of enoxacin concentration in serum and sputum for 400-mg versus 600-mng doses are shown in Fig. 1 and 2 . The mean ratios of enoxacin concentrations in sputum to those in serum at the various time intervals for all groups were as follows: at 2 h, 0.55 ± 0.34; at 5 h, 1.04 ± 0.72; at 9 h, 0.97 ± 0.62.
DISCUSSION
Enoxacin, like other new quinolones, has major advantages over the parent compound nalidixic acid, in greater in vitro antibacterial activity (2) and improvement in pharmacokinetics and tissue distribution (1, 7) . Enoxacin does have in vitro activity against many respiratory pathogens (Wise, Quinolones Bull. June: [1] [2] 1985) and may be useful in severe respiratory infections, even in patients with nosocomial pneumonias and cystic fibrosis. In vitro studies should be complemented with information on distribution of the drug in respiratory tract tissues and secretions.
Although the clinical significance of measuring drug concentrations in bronchial secretions is controversial, there are some recent studies correlating outcome of treatment of respiratory infections with antibiotic bronchial concentrations. For instance, the high failure rate of gentamicin in gram-negative-bacterial pneumonia has been attributed to low concentrations in bronchial secretion (8, 10) . Furthermore, increasing the concentration of aminoglycoside in bronchia by direct instillation in the bronchial tree has improved the cure rate of severe gram-negative-bacterial pneumonia (8) .
The results of this study suggest that enoxacin penetrates well into bronchial mucus and that sufficient concentration is achievable with practical doses to treat most respiratory pathogens except for pneumococci. With 600 mg of enoxacin, a mean peak concentration of 4 ,ug/ml is achieved in bronchial secretion, and significant levels are maintained up to 9 h postdose. This concentration is sufficient to inhibit nearly 100% of H. influenzae (MIC for 90% of isolates [MIC90], 0.25 ,ug/ml), Klebsiella pneumoniae and other Enterobacteriaceae (MIC%, 1 ,ug/ml), Legionella pneumophila (MIC90, 0.25 ,ug/ml), over 90% of Pseudomonas aeruginosa (MIC90, 2 to 4 ,ug/ml), and Staphylococcus aureus (MIC%0, 2 ,uwg/ml) (2-4, 9, 11, 12).
Davies et al. (5) found similar results by measuring enoxacin in expectorated sputum. The average concentration in sputum after 600 mg of enoxacin was 3.3 jxg/ml. Since expectorated sputum was used in this study, it is possible that dilution by saliva could account for the slightly lower levels. Adequate bronchial secretion or sputum levels do not necessarily reflect lung tissue levels. However, concentrations of 8 ,ug of enoxacin per ml in lung tissue after a single oral dose of 600 mg have been reported (13) .
In summary, the broad antibacterial spectrum and the encouraging kinetic properties of enoxacin with good concentrations in sputum and lung tissue make this a promising agent in difficult-to-treat respiratory infections such as bronchiectasis, cystic fibrosis, and gram-negative-bacterial pneumonias. The oral preparation allows for outpatient treatment, earlier discharge from the hospital, and potential cost savings. Further studies are required to evaluate and confirm its full potential.
